Timothy L. Moore

September 7, 2026

Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum. Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.

October 15, 2026

Cerus to Present at 2026 AABB Annual Meeting. Cerus Corporation announced it will host a workshop and present abstracts at the upcoming 2026 AABB Annual Meeting. This event highlights the company's ongoing scientific engagement and clinical data sharing within the blood banking community. The announcement serves as a routine corporate update, providing context for the stock's current trading position near its support levels.

September 7, 2026

Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.